These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
368 related items for PubMed ID: 18992144
1. Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5. Li Y, Fan X, Goodwin CR, Laterra J, Xia S. BMC Cancer; 2008 Nov 07; 8():325. PubMed ID: 18992144 [Abstract] [Full Text] [Related]
8. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K, Douglas L, Delaney A, Houghton JA. Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455 [Abstract] [Full Text] [Related]
9. Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines. Chang CC, Kuan CP, Lin JY, Lai JS, Ho TF. Chem Res Toxicol; 2015 Aug 17; 28(8):1574-83. PubMed ID: 26203587 [Abstract] [Full Text] [Related]
11. Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs. Jayasooriya RG, Choi YH, Hyun JW, Kim GY. Environ Toxicol Pharmacol; 2014 Nov 17; 38(3):959-67. PubMed ID: 25461556 [Abstract] [Full Text] [Related]
12. Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth. Cai W, Rook SL, Jiang ZY, Takahara N, Aiello LP. Invest Ophthalmol Vis Sci; 2000 Jun 17; 41(7):1885-93. PubMed ID: 10845613 [Abstract] [Full Text] [Related]
13. Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Li Y, Guessous F, Johnson EB, Eberhart CG, Li XN, Shu Q, Fan S, Lal B, Laterra J, Schiff D, Abounader R. Lab Invest; 2008 Feb 17; 88(2):98-111. PubMed ID: 18059365 [Abstract] [Full Text] [Related]
16. Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells. Shlyakhtina Y, Pavet V, Gronemeyer H. Cell Death Dis; 2017 Aug 31; 8(8):e3025. PubMed ID: 29048428 [Abstract] [Full Text] [Related]
17. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B. Mol Cancer Res; 2009 Nov 31; 7(11):1835-44. PubMed ID: 19843632 [Abstract] [Full Text] [Related]
18. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Chen X, Kandasamy K, Srivastava RK. Cancer Res; 2003 Mar 01; 63(5):1059-66. PubMed ID: 12615723 [Abstract] [Full Text] [Related]
19. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Kim YH, Jung EM, Lee TJ, Kim SH, Choi YH, Park JW, Park JW, Choi KS, Kwon TK. Free Radic Biol Med; 2008 Mar 15; 44(6):1055-68. PubMed ID: 18164688 [Abstract] [Full Text] [Related]
20. The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells. Nathwani SM, Greene LM, Butini S, Campiani G, Williams DC, Samali A, Szegezdi E, Zisterer DM. Int J Oncol; 2016 Jul 15; 49(1):74-88. PubMed ID: 27176505 [Abstract] [Full Text] [Related] Page: [Next] [New Search]